Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Acquired by HighTower Advisors LLC

HighTower Advisors LLC lifted its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 4.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,708 shares of the company’s stock after acquiring an additional 774 shares during the period. HighTower Advisors LLC’s holdings in Prestige Consumer Healthcare were worth $1,215,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Boston Trust Walden Corp purchased a new position in shares of Prestige Consumer Healthcare in the 3rd quarter worth about $41,785,000. Ariel Investments LLC raised its holdings in shares of Prestige Consumer Healthcare by 10.7% in the 2nd quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock worth $195,204,000 after purchasing an additional 274,212 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in shares of Prestige Consumer Healthcare by 26.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company’s stock worth $90,891,000 after purchasing an additional 272,773 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Prestige Consumer Healthcare by 9.0% in the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after purchasing an additional 171,357 shares during the period. Finally, F M Investments LLC purchased a new position in shares of Prestige Consumer Healthcare in the 2nd quarter worth about $11,162,000. 99.95% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PBH. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a report on Monday, December 9th. StockNews.com downgraded Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Finally, DA Davidson reiterated a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Hold” and a consensus target price of $85.25.

Prestige Consumer Healthcare Trading Down 0.4 %

NYSE:PBH opened at $81.99 on Tuesday. Prestige Consumer Healthcare Inc. has a 12-month low of $57.95 and a 12-month high of $86.36. The firm has a market capitalization of $4.05 billion, a P/E ratio of 19.95, a P/E/G ratio of 2.32 and a beta of 0.49. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The business has a 50 day simple moving average of $78.12 and a 200 day simple moving average of $72.61.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same quarter in the previous year, the firm posted $1.07 EPS. The firm’s quarterly revenue was down .9% on a year-over-year basis. Equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current year.

Insider Transactions at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 9,885 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the sale, the senior vice president now directly owns 18,835 shares of the company’s stock, valued at approximately $1,543,904.95. This represents a 34.42 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.